Search research articles
Contact Us
Filters
Showing results (201-210 of 261) with videos related to
Page
of 27
Sort By:
Journal of Immunotherapy and Precision Oncology
|
November 11, 2024
Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma
Shadi Chamseddine, Betul Gok Yavuz, Yehia I Mohamed, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 27, 2018
Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma
Eudocia Q Lee, Dan G Duda, Alona Muzikansky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 31, 2013
Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study
Andrew X Zhu, Marek Ancukiewicz, Jeffrey G Supko, et al.
Journal of the National Cancer Institute
|
August 1, 2013
Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression
Shom Goel, Nisha Gupta, Brian P Walcott, et al.
Gut
|
January 3, 2023
Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences
Shuling Chen, Cheng Huang, Guanrui Liao, et al.
The Oncologist
|
October 30, 2016
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients
Sara M Tolaney, David R Ziehr, Hao Guo, et al.
Oncology
|
July 19, 2023
Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma
Shadi Chamseddine, Yehia I Mohamed, Sunyoung S Lee, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 19, 2015
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
Sara M Tolaney, Yves Boucher, Dan G Duda, et al.
JCO Global Oncology
|
April 22, 2020
Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma
Sarinya Kongpetch, Apinya Jusakul, Jing Quan Lim, et al.
Theranostics
|
February 22, 2018
Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development
Yun-Chieh Sung, Ya-Chi Liu, Po-Han Chao, et al.
Page
of 27
Search research articles
Search
Showing results (201-210 of 261) with videos related to
Sort By:
Page
of 27
Journal of Immunotherapy and Precision Oncology
|
November 11, 2024
Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma
Shadi Chamseddine, Betul Gok Yavuz, Yehia I Mohamed, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 27, 2018
Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma
Eudocia Q Lee, Dan G Duda, Alona Muzikansky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 31, 2013
Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study
Andrew X Zhu, Marek Ancukiewicz, Jeffrey G Supko, et al.
Journal of the National Cancer Institute
|
August 1, 2013
Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression
Shom Goel, Nisha Gupta, Brian P Walcott, et al.
Gut
|
January 3, 2023
Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences
Shuling Chen, Cheng Huang, Guanrui Liao, et al.
The Oncologist
|
October 30, 2016
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients
Sara M Tolaney, David R Ziehr, Hao Guo, et al.
Oncology
|
July 19, 2023
Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma
Shadi Chamseddine, Yehia I Mohamed, Sunyoung S Lee, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 19, 2015
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
Sara M Tolaney, Yves Boucher, Dan G Duda, et al.
JCO Global Oncology
|
April 22, 2020
Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma
Sarinya Kongpetch, Apinya Jusakul, Jing Quan Lim, et al.
Theranostics
|
February 22, 2018
Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development
Yun-Chieh Sung, Ya-Chi Liu, Po-Han Chao, et al.
Page
of 27